查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球孤儿药市场 2023-2030
市场调查报告书
商品编码
1380385

全球孤儿药市场 2023-2030

Global Orphan Drugs Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 210 Pages | 商品交期: 2-3个工作天内

价格

全球孤儿药市场预计在预测期内（2023-2030年）CAGR为11.8%。市场的成长归因于全球孤儿药的重要性和目的。孤儿药是为治疗特定罕见疾病而开发的药理化合物。极少数患者通常患有上述罕见疾病。由于患者基数较小，如果没有政府的援助和激励，这些药物的开发在经济上可能不可行。根据 BMJ 报导，2023 年 5 月，一种被称为孤儿药的药物被开髮用于治疗特定的罕见疾病。除了患有这些疾病的患者数量极少之外，如果没有政府的援助，孤儿药的开发也无法在商业上可行。孤儿药预计将占全球所有处方药销售额（不包括仿製药）的 20%，年市场成长率为 11.7%，而非孤儿药为 5.9%。然而，随着遗传学和精准医学的发展，使用越来越有限的疾病术语来为越来越多的药物提供孤儿地位，引起了人们的担忧。此外，由于癌症在全球的流行，每年报告有 1400 万新病例和 800 万人死于癌症。对创新和有效的癌症治疗的需求正在迅速增长，据估计，到 2040 年，病例数可能会增加到 2,200 万。最终，由于消费者基础有限，罕见癌症的治疗有时很难获得所需的资金。

细分市场前景

全球孤儿药市场按药物类型、疾病类型和配销通路进行细分。根据疾病类型，市场分为生物和非生物。根据疾病类型，市场细分为肿瘤学、血液学、神经学、心血管学等。此外，根据配销通路，市场分为医院药房、零售药房、网路药房等。肿瘤学子类别预计将占据疾病类型细分市场的很大一部分市场份额。这归因于肿瘤疾病盛行率的增加、癌症意识的提高、早期癌症筛检以及用于癌症治疗的肿瘤孤儿药物的可用性。

预计心血管细分市场将在全球孤儿药市场中占据相当大的份额

在疾病类型中，心血管细分市场预计将在全球孤儿药市场中占据相当大的份额。细分市场的成长归因于对心血管健康的考虑。钠摄取量增加与多种心血管危险因素，特别是高血压（高血压）直接相关。有趣的是，XywavTM 的钠含量较低，这与摄取过量钠相关的更广泛的健康问题不谋而合。例如，2021年6月，Jazz Pharmaceuticals plc推出了XywavTM（钙、镁、钾和钠羟丁酸盐）口服溶液，用于治疗7岁及以上发作性睡病患者的猝倒或日间过度嗜睡（ EDS）。美国食品药物管理局 (FDA) 已授予七年孤儿药独占权。 Xywav（一种羟丁酸盐产品）的钠含量比建议剂量范围为 6 至 9 克（或约 1,000 至 1,500 毫克/晚）的羟丁酸钠低 92%。

区域展望

全球孤儿药市场根据地理位置进一步细分，包括北美（美国和加拿大）、欧洲（英国、义大利、西班牙、德国、法国和欧洲其他地区）、亚太地区（印度、中国、日本） 、韩国和亚洲其他地区）以及世界其他地区（中东和非洲以及拉丁美洲）。其中，由于政府增加社区健康和肿瘤中心数量的倡议，预计亚太地区将在全球市场中占据显着份额，预计将扩大新兴国家的孤儿药市场。

预计欧洲地区全球孤儿药市场将以显着的复合CAGR成长

在所有地区中，欧洲地区预计在预测期内将以相当大的CAGR成长。区域增长归因于该地区罕见疾病范围的广泛增加。迄今为止已发现的 7000 多种罕见疾病中，大多数都有遗传基础。由于其中几种疾病被认为是有害的，因此有效治疗的紧迫性越来越大。根据 Pharmaceutical Technology 报告，截至 2022 年 7 月，据信目前存在 7,000 多种罕见疾病，其中大多数是遗传性的，其中许多被认为危及生命。根据欧盟的定义，孤儿病儘管患病率很高，但约有 2,000 人患有此病。

市场参与者展望

服务于孤儿药市场的主要公司包括：阿斯特捷利康(AstraZeneca)、罗氏(F. Hoffmann-La Roche Ltd)、拜耳(Bayer)、百时美施贵宝印度私人有限公司(Bristol-Myers Squibb India Pvt.) 。株式会社、第一三共株式会社等。市场参与者透过各种策略（包括併购、合作、合作、融资和新产品发布），为市场成长做出了巨大贡献，以保持市场竞争力。例如，2021 年 11 月，Emmes 推出了新中心 Orphan Reach，作为独特的「稀有 CRO」。该公司以精通公共部门和生物製药行业的公共卫生研究而闻名，并已被纳入新的罕见疾病中心。

报告涵盖：

  • 2022年市场价​​值资料分析及2030年预测。
  • 每个细分市场的年化市场收入（百万美元）。
  • 主要地理区域的国家分析。
  • 在全球孤儿药市场营运的主要公司。根据现有资料，报告中还提供了与新产品发布相关的资讯以及相关新闻。
  • 透过确定未来强劲成长的关键细分市场来分析业务策略。
  • 市场进入和市场扩张策略分析。
  • 透过识别市场中「谁的立场」来制定竞争策略。

目录

第 1 章：报告摘要

  • 目前行业分析及成长潜力展望
  • 研究方法和工具
  • 市场区隔
    • 按细分
    • 按地区

第 2 章：市场概述与见解

  • 报告范围
  • 分析师见解和当前市场趋势
    • 主要发现
    • 建议
    • 结论

第 3 章：竞争格局

  • 主要公司分析
  • AbbVie Inc.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Alexion Pharmaceuticals, Inc.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Amgen Inc.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • 关键策略分析

第 4 章：市场细分

  • 按药物类型分類的全球孤儿药市场
    • 生物
    • 非生物的
  • 按疾病类型分類的全球孤儿药市场
    • 肿瘤学
    • 血液学
    • 神经病学
    • 心血管
    • 其他（自体免疫疾病和罕见血液疾病）
  • 按配销通路分類的全球孤儿药市场
    • 医院药房
    • 零售药房
    • 网路药房
    • 其他（专业药房和直接面向患者的分销）

第 5 章：区域分析

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 义大利
    • 西班牙
    • 法国
    • 欧洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 世界其他地区

第 6 章：公司简介

  • AstraZeneca.
  • At F. Hoffmann-La Roche Ltd
  • Bayer AG
  • Bristol-Myers Squibb India Pvt. Ltd.
  • Daiichi Sankyo Co. Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson Pvt. Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Takeda Pharmaceutical Co. Ltd.
Product Code: OMR2027794

Title: Global Orphan Drugs Market Size, Share & Trends Analysis Report by Drug Type (Biological, and Non-biological), by Disease Type (Oncology, Hematology, Neurology, Cardiovascular, and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others),Forecast Period (2023-2030).

The global orphan drugs market is anticipated to grow at a CAGR of 11.8% during the Forecast Period (2023-2030). The market's growth is attributed to significance and purpose of orphan drugs across the globe. Orphan pharmaceuticals are pharmacological compounds developed to treat particular rare medical conditions. A minimal number of patients normally suffer the aforementioned rare disorders. These medications can be financially unviable to develop without government assistance and incentives owing to their small patient bases. According to the BMJ, in May 2023, a pharmacological agent referred to as an orphan drug that has been developed to treat specific rare medical diseases. In addition to the tiny number of patients with the diseases, an orphan medicine cannot be made commercially viable to develop without government aid. Orphan medications are projected to account for 20% of all prescription drug sales globally (excluding generics), with an annual market growth rate of 11.7% vs 5.9% for non-orphan drugs. The use of increasingly limited disease terms to provide orphan status to a growing number of medications, rendered accessible by developments in genetics and precision medicine, raised concerns, though. Furthermore, 14 million new cases and 8 million fatalities from cancer are reported annually owing to its global prevalence. The demand for innovative and potent cancer treatments is increasing rapidly as estimates indicate that the number of cases can rise to 22 million by the year 2040. Ultimately, owing to their limited consumer base, treatments for uncommon cancers sometimes struggle to acquire the funding they demand.

Segmental Outlook

The global orphan drugs market is segmented on the drug type, disease type, and distribution channel. Based on the disease type, the market is sub-segmented into biological, and non-biological. Based on the disease type, the market is sub-segmented into oncology, hematology, neurology, cardiovascular, and others. Furthermore, on the basis of distribution channel, the market is sub-segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others. The oncology subcategory is expected to capture a significant portion of the market share within the disease type segment. This is attributed to the increase in the prevalence of oncological diseases, increased awareness of cancer, early cancer screening, and the availability of oncological orphan medications for cancer treatment.

The Cardiovascular Sub-Segment is Anticipated to Hold a Considerable Share of the Global Orphan Drugs Market

Among the disease type, the cardiovascular sub-segment is expected to hold a considerable share of the global orphan drugs market. The segmental growth is attributed to the considerations for cardiovascular health. Increased sodium consumption has a direct correlation with several cardiovascular risk factors, particularly hypertension (high blood pressure). It is interesting that XywavTM has less sodium that coincides with broader health concerns related to consuming excessive sodium. For instance, in June 2021, Jazz Pharmaceuticals plc, launched the XywavTM (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. The U.S. Food and Drug Administration (FDA) has recognized seven years of Orphan Drug Exclusivity. The sodium content of Xywav, an oxybate product, is 92% lower than that of sodium oxybate in the recommended dosage range of 6 to 9 grams, or roughly 1,000 to 1,500 mg/night.

Regional Outlook

The global orphan drugs market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia-Pacific is anticipated to hold a prominent share of the market across the globe, owing to the increased government initiatives to boost the number of community health and oncology centers are anticipated to expand the market for orphan medications in emerging nations.

The Europe Region is Expected to Grow at a Significant CAGR in the Global Orphan Drugs Market

Among all regions, the Europe regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the rising wide range of orphan diseases across the region. The majority of the more than 7,000 orphan diseases that have been identified so far have genetic bases. There is an increased urgency for effective treatments owing to several of these diseases are thought to be harmful. According to Pharmaceutical Technology, in July 2022, More than 7,000 orphan diseases are believed to exist at the moment, the majority of that are genetic in origin and many of that are regarded as life-threatening. Orphan diseases, as defined by the European Union, afflict approximately in 2,000 individuals, despite their significant prevalence.

Market Players Outlook

The major companies serving the orphan drugs market include: AstraZeneca., At F. Hoffmann-La Roche Ltd, Bayer AG, Bristol-Myers Squibb India Pvt. Ltd., Daiichi Sankyo Co. Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance in November 2021, Emmes launched its new center, Orphan Reach as a unique 'rare CRO'. The company renowned for proficiency in public health research across the public sector and biopharmaceutical industry has been included into the new rare diseases center.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global orphan drugs market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. AbbVie Inc.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Alexion Pharmaceuticals, Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Amgen Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Orphan Drugs Market by Drug Type
    • 4.1.1. Biological
    • 4.1.2. Non-biological
  • 4.2. Global Orphan Drugs Market by Disease Type
    • 4.2.1. Oncology
    • 4.2.2. Hematology
    • 4.2.3. Neurology
    • 4.2.4. Cardiovascular
    • 4.2.5. Others (Autoimmune Diseases, and Rare Blood Disorders)
  • 4.3. Global Orphan Drugs Market by Distribution Channel
    • 4.3.1. Hospital Pharmacy
    • 4.3.2. Retail Pharmacy
    • 4.3.3. Online Pharmacy
    • 4.3.4. Others (Specialty Pharmacies, and Direct-to-Patient Distribution)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. AstraZeneca.
  • 6.2. At F. Hoffmann-La Roche Ltd
  • 6.3. Bayer AG
  • 6.4. Bristol-Myers Squibb India Pvt. Ltd.
  • 6.5. Daiichi Sankyo Co. Ltd.
  • 6.6. GlaxoSmithKline plc
  • 6.7. Johnson & Johnson Pvt. Ltd.
  • 6.8. Novartis AG
  • 6.9. Pfizer Inc.
  • 6.10. Sanofi
  • 6.11. Takeda Pharmaceutical Co. Ltd.

LIST OF TABLES

  • 1. GLOBAL ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 2. GLOBAL BIOLOGICAL ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL NON-BIOLOGICAL ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2022-2030 ($ MILLION)
  • 5. GLOBAL ORPHAN DRUGS IN ONCOLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL ORPHAN DRUGS IN HEMATOLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL ORPHAN DRUGS IN NEUROLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL ORPHAN DRUGS IN CARDIOVASCULAR MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL ORPHAN DRUGS IN OTHER DISEASE TYPES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 11. GLOBAL ORPHAN DRUGS BY HOSPITAL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 12. GLOBAL ORPHAN DRUGS BY RETAIL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 13. GLOBAL ORPHAN DRUGS BY ONLINE PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. GLOBAL ORPHAN DRUGS BY OTHER DISTRIBUTION CHANNELS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. GLOBAL ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 16. NORTH AMERICAN ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 17. NORTH AMERICAN ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2022-2030 ($ MILLION)
  • 19. NORTH AMERICAN ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 20. EUROPEAN ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 21. EUROPEAN ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 22. EUROPEAN ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE , 2022-2030 ($ MILLION)
  • 23. EUROPEAN ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 24. ASIA- PACIFIC ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 25. ASIA- PACIFIC ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 26. ASIA- PACIFIC ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2022-2030 ($ MILLION)
  • 27. ASIA- PACIFIC ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2022-2030 ($ MILLION)
  • 28. REST OF THE WORLD ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD ORPHAN DRUGS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL , 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL ORPHAN DRUGS MARKET SHAREBY DRUG TYPE, 2022 VS 2030 (%)
  • 2. GLOBAL BIOLOGICAL ORPHAN DRUGS MARKET SHAREBY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL NON-BIOLOGICAL ORPHAN DRUGS MARKET SHAREBY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL ORPHAN DRUGS MARKET SHAREBY DISEASE TYPE, 2022 VS 2030 (%)
  • 5. GLOBAL ORPHAN DRUGS IN ONCOLOGY MARKET SHAREBY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL ORPHAN DRUGS IN HEMATOLOGY MARKET SHAREBY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL ORPHAN DRUGS IN NEUROLOGY MARKET SHAREBY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL ORPHAN DRUGS IN CARDIOVASCULAR MARKET SHAREBY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL ORPHAN DRUGS IN OTHER DISEASE TYPES MARKET SHAREBY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL ORPHAN DRUGS MARKET SHAREBY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
  • 11. GLOBAL ORPHAN DRUGS BY HOSPITAL PHARMACY MARKET SHAREBY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL ORPHAN DRUGS BY RETAIL PHARMACY MARKET SHAREBY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL ORPHAN DRUGS BY ONLINE PHARMACY MARKET SHAREBY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL ORPHAN DRUGS FOR OTHER DISTRIBUTION CHANNELS MARKET SHAREBY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL ORPHAN DRUGS MARKET SHAREBY REGION, 2022 VS 2030 (%)
  • 16. US ORPHAN DRUGS MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. CANADA ORPHAN DRUGS MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. UK ORPHAN DRUGS MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. FRANCE ORPHAN DRUGS MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. GERMANY ORPHAN DRUGS MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. ITALY ORPHAN DRUGS MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. SPAIN ORPHAN DRUGS MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. REST OF EUROPE ORPHAN DRUGS MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. INDIA ORPHAN DRUGS MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. CHINA ORPHAN DRUGS MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. JAPAN ORPHAN DRUGS MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. SOUTH KOREA ORPHAN DRUGS MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. REST OF ASIA-PACIFIC ORPHAN DRUGS MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD ORPHAN DRUGS MARKET SIZE, 2022-2030 ($ MILLION)